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Abstract
Background: Approximately 3% of people receiving opioid substitution therapy (OST) in the UK manage to achieve
abstinence from prescribed and illicit drugs within three years of commencing treatment. Involvement of families
and wider social networks in supporting psychological treatment may be an effective strategy in facilitating
recovery, and this pilot study aimed to evaluate the impact of a social network-focused intervention for patients
receiving OST.
Methods: A two-site, open feasibility trial randomised patients receiving OST for at least 12 months but still reporting
illicit opiate use in the past 28 days to one of three treatments: 1) treatment as usual (TAU), 2) Brief Social Behaviour
and Network Therapy (B-SBNT) + TAU, or 3) Personal Goal Setting (PGS) + TAU. The two active interventions consisted
of 4 sessions. There were 3 aims: 1) test the feasibility of recruiting OST patients to a trial of B-SBNT, and following them
up over 12 months; 2) test the feasibility of training clinicians to deliver B-SBNT; 3) test whether B-SBNT reduces heroin
use 3 and 12 months after treatment, and to explore potential mediating factors. The primary outcome for aim 3 was
number of days of heroin use in the past month, and a range of secondary outcome measures were specified in
advance (level of drug dependence, mental health, social satisfaction, therapist rapport, treatment satisfaction, social
network size and support).
Results: A total of 83 participants were randomised, and 70 (84%) were followed-up at 12 months. Fidelity analysis of
showed that B-SBNT sessions were clearly distinguishable from PGS and TAU sessions, suggesting it was possible to
train clinical staff to an adequate level of competence.
No significant differences were found between the 3 intervention arms in the primary or secondary outcome
measures. Attendance at psychosocial treatment intervention sessions was low across all three arms (44% overall).
Conclusions: Patients receiving OST can be recruited into a trial of a social network-based intervention, but poor
attendance at treatment sessions makes it uncertain whether an adequate dose of treatment was delivered. In order
to achieve the benefits of psychosocial interventions, further work is needed to overcome poor engagement.
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Background
The first decade of the twenty-first century saw a step
change in the size and scope of treatment services for
illicit drug users in England, with increased financial in-
vestment leading to a doubling of the number of people in
treatment in the period 2000–2005 alone [1]. The political
drive behind this change was a desire to reduce criminal
activity, but with a newly-elected UK Government in 2010
came a change in direction. Since then there has been
more focus on ‘recovery’, with a national strategy requiring
treatment agencies to focus on increasing the number of
patients leaving their service abstinent from all illicit and
prescribed drugs, in good mental and physical health, and
with improved quality of life [2]. Supporters of this ap-
proach noted that this goal was rarely achieved, with only
3% of people reporting abstinence within three years of
starting opiate substitution treatment (OST) in one study
in Scotland [3]. Treatment services often focused on
medication to the exclusion of effective psychosocial inter-
ventions for the opiate dependent population [4], and one
large-scale attempt to evaluate Cognitive Behavioural
Therapy in OST clinics identified major training and or-
ganisational barriers [5].
The social environment can directly support and
reinforce drug use, particularly if a majority of an individ-
ual’s social network is made up of other drug users [6–9].
One potential strategy to support abstinence from illicit
drugs is to encourage patients of OST services to end all
contact with drug-using peers. However, this is unlikely to
happen if no alternative social contact or support is avail-
able, and so psychosocial treatment approaches have
begun to focus on building links to individuals and groups
who provide competitive reinforcement for abstinence.
When this is done successfully, the development of new
positive social supports is associated with a reduced risk
of relapse to heroin and other drug use and better overall
outcomes [10–14].
The important role of families and communities in re-
covery from drug use has been emphasised in recent
treatment policy in England [15, 16], with the National
Treatment Agency for Substance Misuse (NTA) signal-
ling its enthusiasm for involving families and other so-
cial network members in the treatment process (pp. 15)
[17]. However, despite support for change from both re-
searchers and policy makers, drug treatment agencies
tend to focus on the individual rather than the family or
wider community. Further work is needed to develop
and evaluate treatment interventions that aim to build
social support for change in substance use and other
behaviours, but also to understand the barriers to imple-
menting such an approach. In an increasingly pressured
financial environment, psychosocial interventions must
be feasible in routine clinical practice and acceptable to
both service users and clinicians. They must also move
beyond merely targeting changes in drug use, but focus
on the pursuit of the wider goal of recovery, including
mental and physical health, employment and quality of
life [18]).
We report the findings of a pilot trial with the aim of
implementing, observing and assessing the efficacy of a
social-network intervention (Brief-Social Behaviour and
Network Therapy – B-SBNT) for both opiate substitu-
tion treatment patients and their social network mem-
bers. This paper reports on three of the trial’s main
objectives:
1. To test the feasibility of recruiting patients engaged
in drug treatment services for at least a year but still
reporting heroin use to a trial of B-SBNT, and fol-
lowing them up over 12 months.
2. To test the feasibility of training NHS clinicians with
no previous experience of working with social
network members to deliver a brief social network-
driven intervention (B-SBNT).
3. To test whether B-SBNT reduces heroin use 3 and
12 months after treatment, and to explore potential
mediating factors.
The full study evaluation also included a comprehen-
sive economic evaluation which has been published
elsewhere [19, 20].
Method
Design
This early phase open pilot study had a pragmatic, mul-
ticentre, randomised parallel group design, comparing a
4-session social network intervention (B-SBNT) with an
individually-based personal goal setting intervention of
equivalent intensity (PGS), and with treatment as usual
(TAU). It targeted patients receiving OST for more than
12 months but still reporting opiate use in the preceding
28 days, and was conducted within three National
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Health Service (NHS) community drug treatment teams
in two UK regions; the West Midlands (Solihull and
Birmingham) and the East Midlands (Leicester).
Intervention
Participants allocated to either of the active treatment
groups received an intervention as an adjunct to usual
care, delivered by a different therapist to the participant’s
usual drug worker.
1. Treatment as usual (TAU):
In the control arm participants received usual care
with no additional therapy sessions. The treatment
services allowed the clinicians to utilise a therapeutic
style of their choice for working with patients, and TAU
sessions did not follow a treatment manual. Some drug
workers had been exposed to goal setting and SBNT
techniques as part of their previous training and devel-
opment. However, previous evaluation in these services
had shown that TAU sessions occurred between weekly
and fortnightly, lasted an average of 45 min, and
focussed on case management, signposting of other
services, and other activities such as medication issues
[21]. Therefore TAU would consist of interventions that
were both less structured and less frequent than the two
active treatments.
2. Brief Social Behaviour and Network Therapy (B-
SBNT) ± TAU:
Social Behaviour and Network Therapy (SBNT) is built
on the idea that social support for change is central to
resolving substance dependence and seeks to involve
close friends and family as part of the treatment process
[22]. The approach was shown to be effective and cost--
effective in the large UK Alcohol Treatment Trial
(UKATT) [23, 24]. Subsequently, therapists from
community drug services in Birmingham were trained to
deliver the intervention at a two-day training workshop
and then guided by a written manual and supervision
using video-recordings of sessions. An evaluation con-
cluded that it was feasible to train 12 therapists to
deliver SBNT, with the participating patients reporting a
reduction in drug use and improved family and social re-
lationships at the 3-month follow-up point [25].
Originally SBNT was developed as an 8-session inter-
vention, although in reality 64% of the UKATT sample
(n = 320) received no more than 4 sessions [26]. Some of
the most important components occur during the early
part of the treatment e.g. drawing a social network dia-
gram; contacting and inviting people; reviewing commu-
nication and interactions with significant network
members. The original intervention manual [25] was
therefore adapted for the current study using a four ses-
sion format, and is hereafter referred to as Brief Social
Behaviour and Network Therapy (B-SBNT). The most
effective components of the SBNT intervention [26]
were combined with elements of node-link mapping [27]
to facilitate the training and delivery of the intervention.
The therapist worked with the patient to draw a ‘social
network diagram’ during the first session in order to
identify potential social support for change that could be
drawn upon in later sessions [28]. Network members
identified by the participant were then approached and
invited to take part in treatment sessions, and the
therapist used elements of communication skill develop-
ment, coping behaviours and the development of joint
activities to support the development of a network-
supported relapse management plan. B-SBNT was deliv-
ered by a trained clinician that wasn’t the patient’s usual
key worker. Participants were invited to attend four 50-
min B-SBNT sessions over a period of 6 weeks, in
addition to TAU sessions with their usual keyworker.
They were asked to nominate at least one ‘network’
member who would then be actively encouraged to
participate in subsequent sessions.
3. Personal Goal Setting (PGS) ± TAU:
PGS involved an additional active component to usual
care through a structured process of setting personal
goals and monitoring their attainment. This arm was in-
cluded to control for the intensity of treatment in the B-
SBNT arm and the process of receiving the intervention
from a different therapist. PGS consisted of four 50-min
sessions over a period of 6 weeks delivered according to
a purpose designed manual [29] by a trained clinician. It
was based on the principles of node-link mapping [27]
and included a review of the participant’s current situ-
ation and future aspirations, the development of
SMART (Specific, Measurable, Agreed-upon, Realistic,
Time-limited) goals, and monitoring and feedback on
progress in achieving these goals.
Treatment monitoring and fidelity
To ensure that B-SBNT and PGS were delivered with
sufficient fidelity, all trial therapists were required to
participate in monthly supervision meetings with
research clinicians. Each therapeutic session with the
therapist was audio recorded, with a proportion ran-
domly selected for fidelity assessment using the UKATT
Process Rating Scale [30].
Staff recruitment & training
As the aim of the study was to test the feasibility of
training staff to deliver a social network intervention, no
attempt was made to randomly select therapists and
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clinicians volunteered to participate. They were trained
using the process adopted in previous SBNT pilot work
[25], with an initial one-day training session to introduce
the key concepts and procedures involved in each treat-
ment intervention. All staff delivering B-SBNT were
then required to pilot the methods with one clinical case
prior to the commencement of the trial. Monthly 90-
min group supervision sessions were provided for both
active treatment conditions, and clinicians brought
node-link maps developed in the session to guide
discussion.
Participant recruitment & randomisation
Inclusion and exclusion criteria
Each potential participant had to (1) be 18 years or
older; (2) have been prescribed OST (methadone or
buprenorphine) continuously for the past 12 months; (3)
report use of heroin on one or more days in the previous
28 days; (4) give informed consent to participation. The
only reason for exclusion was a severe co-morbid mental
or physical health issue that prevented an individual
from participating in treatment sessions. Any such cases
were discussed with clinicians at the time of screening.
The Treatment Outcome Profile (TOP) assessment is
completed every 3–6 months for all patients receiving
specialist substance misuse treatment in England [31],
and includes questions about use of illicit opiates. These
data are stored as part of the patient’s electronic record
unless the patient has refused consent to share this
information, and so the research team were able to iden-
tify individuals that met the study inclusion criteria by
reviewing the case record every 6 weeks. A list of poten-
tial participants was given to clinical staff in each partici-
pating team, and the patient was given an initial
overview and written information about the study at
their next routine appointment with their usual clinician.
If the patient expressed an interest they were contacted
by a researcher who provided further information and
invited them to sign a consent form. Patients were
randomised and allocated to treatment intervention
following completion of the baseline interview. A
dynamic randomisation algorithm was used, minimizing
differences in the numbers allocated to each experimen-
tal group [32]. As this was an open trial, randomisation
was not stratified by investigational site as this would
not be properly concealed, and was done using a secure,
remote randomisation service independent of the
research team.
Assessments
Assessment was conducted before treatment randomisa-
tion (baseline), and at 3 and 12 months post-baseline.
Sociodemographic data was only collected at baseline,
and included age, sex, ethnicity, employment status, and
living situation. Ten other instruments were adminis-
tered at all three time points, and further details are
given in the study protocol [33].
(i) Illicit drug use: section B of the Maudsley Addiction
Profile (MAP) [34] was used to quantify the number
of days on which heroin, cocaine, benzodiazepine or
alcohol was used in the previous 28 days, and the
average amount of use of each drug on each using
day. A urine sample was taken to test for heroin,
methadone, buprenorphine, cocaine and
benzodiazepines.
(ii)Health risk behaviour: section C of the MAP [34] to
quantify the number of days on which drugs were
injected in the previous 28 days.
(iii) Drug-related problems: section E of the MAP [34]
was used to quantify the number of days of work
and acquisitive crime in the previous 28 days.
(iv) Severity of drug dependence: the Leeds
Dependence Questionnaire (LDQ) [35] is validated
in drug users and is composed of 10 questions that
are summed to give a maximum score of 30. A
higher score indicates greater dependence.
(v) Psychological functioning: measured using three
domains of the Clinical Outcome in Routine
Evaluation (CORE-OM) scale [36] (a) well-being (4
items); (b) symptoms (12 items: 4 depression, 4 anx-
iety, 2 trauma, 2 physical); (c) functioning (12 items
– 4 general functioning, 4 functioning in social rela-
tionships, 4 functioning in close relationships). Each
item is scored between 0 and 4, and a mean score is
reported for each domains.
(vi) Social functioning: the Social Satisfaction
Questionnaire (SSQ) [37] is an 8-item self-complete
questionnaire that measures perceived social prob-
lems. The maximum score is 24, and higher scores
represent greater satisfaction with housing, finances
or relationships.
(vii) Motivation to change behaviour: the Readiness to
Change Questionnaire–Treatment Version (RTCQ-
TV) [38] is a 15-item questionnaire that allows the
assignment of substance users to one of the stages
described in Prochaska and DiClemente’s model of
change (i.e. Precontemplation, Contemplation or
Action) [39].
(viii) Social network structure and function: the Important
People Drug & Alcohol Interview (IPDA) [14] is a
researcher-administered instrument that requires re-
spondents to provide the first name and relationship
of up to 10 members of their social network who
have been important to them in the previous three
months. For each network member identified the re-
spondent then rates their frequency of contact, im-
portance, general support, frequency of use of drugs
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or alcohol, and their reaction to the participant’s sub-
stance use and treatment.
(ix) General social support: the Interpersonal Support
Evaluation List (ISEL) [40] is a self-completion in-
strument that requires the participant to rate 40
statements about the availability of possible social re-
sources. Four 10-item subscales are then generated,
measuring ‘Tangible’ support, ‘Appraisal’ support,
‘Self-esteem’ support, and ‘Belonging’ support. Each
subscale is scored between 0 and 30, where a higher
score indicates a greater perception of support.
(x)Therapeutic engagement: the 36 items that make up
the Engagement section of the Client Evaluation of
Self and Treatment (CEST) [41] were completed by
the participant, with each item scored between 1
and 5. This generated 4 sub-scale scores representing
‘Treatment Participation’, ‘Treatment Satisfaction’,
‘Counselling Rapport’, and ‘Peer Support’.
Sample size
As this was a pilot feasibility study, a formal sample
size calculation was not appropriate. However, by
using a recruitment goal of 120 participants (i.e. 40 in
each treatment arm), we calculated that if the propor-
tion of patients that stopped taking heroin in the B-
SBNT group was 0.3 (e.g. 30%), this would produce
an approximate 95% confidence interval of 0.18–0.44
(e.g. 18% to 44%) for this estimate. Alternatively, if
the proportion was found to be 0.1 (e.g. 10%), an
approximate 95% confidence interval would be 0.01–
0.19 (e.g. 1% to 19%).
Data analysis
Trial outcome analysis
Data was analysed according to the intention-to-treat
principle; all randomised participants were included in
the analysis irrespective of whether they stayed in the
trial or not, with missing data treated as failing to
achieve the outcome. The major analyses were pre-
specified in a statistical analysis plan completed prior to
database lock. Analyses were conducted in SAS 9.2 or
above (www.sas.com/software/sas9). The primary
outcome measure was the number of days that the par-
ticipant had used heroin in the previous 28 days. The
primary analyses compared B-SBNT with the other two
arms (PGS and TAU), and subjects were analysed using
a generalised mixed model with Gaussian mixed error
structures, including experimental group as an explana-
tory classification variable. The therapists were included
as random effects [42]. Analysis of continuous secondary
outcomes was conducted using analogous statistical
models, including changes in level of injecting drug use,
criminal activity, psychological symptoms, severity of
drug dependence, motivation for drug abstinence, social
satisfaction, therapeutic engagement, social network
structure and function, and general social support.
Session rating
Each audio-recorded treatment session was rated by the
two independent raters (CB and SA) using a standar-
dised measure of fidelity for SBNT developed for the UK
Alcohol Treatment Trial (UKATT) [30]. Inter-rater reli-
ability was assessed using a two-way mixed, consistency,
average-measures Intra Class Correlations (ICC) [43] to
assess the degree that coders provided consistency in
their ratings of the frequency and quality items across
sessions.
Results
Sample
The study began in NHS services in the metropolitan
areas of Solihull and Leicester. However, the service in
Leicester underwent a re-commissioning process early in
the trial period which led to a large reorganisation that
drew resources away from the study. Staff were un-
certain of their jobs throughout the trial period, and
the disruption to clinical services hampered screening
and recruitment. As a result, the Leicester site man-
aged only 32% of its target of 60 participants, whereas
Solihull recruited 90%. A further site (Birmingham)
was added to compensate for this shortfall, but the
overall recruitment level fell short of the target level
at a total of 83 opiate dependent patients. Figure 1
shows a flow diagram for the trial, consistent with
the Consolidated Standards of Reporting Trials
(CONSORT) 2010 statement [44].
Participants were randomly allocated to SBNT+TAU
(n = 26), PGS + TAU (n = 27) or TAU only (n = 30). The
primary outcome was illicit opiate use, measured by
urine screen and participant self-report. In addition,
participants completed secondary outcome measures at
baseline (n = 83), 3-months (n = 74) and 12-months (n =
70) post-treatment.
Study aims
1. To test the feasibility of recruiting patients engaged
in drug treatment services for at least a year but still
reporting heroin use to a trial of B-SBNT, and follow
them up over 12 months.
The mean age of the sample was 37 years (range 25–
61), and 72 (87%) participants were male. The partici-
pants were predominantly white British (n = 69, 83%),
unmarried (n = 75, 90%), and unemployed (n = 63, 76%).
Seventeen (21%) had been receiving OST for between 12
and 24 months, 40 (48%) between 25 and 60 months,
and 25 (30%) for over 5 years. Most (n = 51, 61%)
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expressed a goal of being abstinent from all opiates (pre-
scribed and illicit) within 12 months. Seventy six of the
participants (82%) were prescribed methadone solution
and 7 (18%) buprenorphine sublingual tablets. The
median dose of methadone was 60 mg/day (range 14 to
106), and the median dose of buprenorphine was 8 mg
(range 6 to 16 mg).
Trial engagement & participation
A total of 1524 patients were treated in the 3 services
during the period of study, and just over a third (552,
36%) were prescribed OST and reported opiate use in
the past month according to the latest TOP. The proto-
col required the patient’s regular key worker to approach
patients meeting the inclusion criteria to enquire about
their interest in participating in the study. Just under
half (269, 49%) were approached, of which 118 (21%)
were willing/able to discuss entering the trial, and 83
(15%) consented to participate. Reasons for refusal
included not wishing to participate in research, not
wanting extra treatment sessions, or having other
commitments such as work or family that prevented
regular attendance.
Research follow-up
Once recruited to the study, the retention rate was good
(84% at 12-months), and the system of tracing partici-
pants by accessing their patient records, contacting their
GP or pharmacist, or liaising with their drug worker was
effective.
2. To test the feasibility of training NHS clinicians
with no previous experience of working with social
network members to deliver a brief social network-
driven intervention (B-SBNT).
Training
Clinicians were asked to volunteer to be trial therapists,
and 16 were trained in the 2 intervention arms (7 B-
SBNT, 9 PGS). The attendance rate at the monthly
group supervision sessions was 66%, and clinicians pre-
sented cases using node-link maps generated in sessions
Fig. 1 Flow diagram for the trial, consistent with the Consolidated Standards of Reporting Trials (CONSORT) 2010 statement
Day et al. BMC Psychiatry  (2018) 18:8 Page 6 of 12
and discussed specific techniques. There was a wide
variation in the number of study cases taken on by each
trained therapist, but SBNT therapists had a median of
2 cases (range 1 to 12), PGS therapists a median of 2
cases (range 1 to 10), and TAU therapists a median of 1
case (range 1 to 4).
Participant engagement
There was a high level of non-attendance at treatment
sessions, with 49% of the planned sessions completed in
the B-SBNT group, 27% in the PGS group and 50% in
the TAU group. Therapists varied in their ability to en-
gage participants in treatment within each trial arm.
Session recordings and fidelity ratings
Overall, participants attended 115 treatment sessions (47
BSBNT, 29 PGS, 39 TAU). Sixty one session recordings
were available for analysis (26 BSBNT, 20 PGS, 4 TAU).
The sessions lasted between 19 and 67 min (M =
34.4 min; see Additional file 1 for session duration by
study arm). Therapy sessions were rated on items meas-
uring Session Management (maintaining structure,
agenda setting, explanation of treatment, reviewing
inter-session change, consistency of problem focus, and
end of sessions summary), Specific Tasks (homework, al-
ternatives to drinking/drug use, social support for
change-general, involvement of others in behaviour
change and identifying support for change), and Therap-
ist Style (therapist as task oriented, therapist as active
agent for change, collaboration, interpersonal focus).
Each of these items was rated on frequency and quality
on Likert scales ranging from 0 to 4. Additionally, raters
recorded the type of treatment maps that were
completed during sessions. Additional file 2 shows the
average ratings for item frequency, quality and number
of maps used per session by study arm. Both raters gave
higher frequency and quality ratings for B-SBNT session
than for PGS or TAU sessions. A greater number of
maps were completed in PGS sessions than in B-SBNT
sessions, while a greater number of maps was completed
in both active study arms compared to TAU.
Each session was rated by the two independent raters.
Inter-rater reliability was assessed using a two-way
mixed, consistency, average-measures Intra Class
Correlations (ICC; McGraw & Wong, 1996) to assess the
degree that coders provided consistency in their ratings of
the frequency and quality items across sessions. The result-
ing ICC’s ranged from .43 to .95 and .41 to .93 for quality
and frequency respectively (see Additional file 3), indicating
that coders had a high degree of agreement for the majority
of variables and suggesting that the majority of variables
were rated similarly across coders (poor consistency for the
item consistency of problem focus only).
3. To test whether B-SBNT reduces heroin use 3 and
12 months after treatment, and to explore potential
mediating factors.
There were no significant changes in the primary
outcome (combined self-report + objective drug use)
between B-SBNT +TAU, GS + TAU, and TAU only at 3-
month and 12-month follow-up (see Table 1). Likewise,
as Table 2 shows, there were no significant differences
between the three groups in any of the secondary out-
come measures at either 3-months or 12-months.
The mean number of appointments offered differed sig-
nificantly between the three arms of the study (B-SBNT
+TAU= 6.2, PGS + TAU= 4, TAU = 2, F = 30.11, p <
0.001), but the mean rates of attendance were not signifi-
cantly different (B-SBNT+TAU= 54%, PGS + TAU= 49%,
TAU = 63%). During the 6-week study period participants
received a mean of 1.8 B-SBNT and 1.1 PGS sessions, in
addition to a mean of 1.3 TAU sessions, representing an
attendance rate of 44% overall. Sixteen participants
(19.2%) attended no sessions at all during the study
period. Eleven (42%) of the 26 participants randomised to
B-SBNT brought a network member to a session (7 for 1
session, 1 for 2 sessions and 3 for 3 sessions), compared
with none in the PGS and one in the TAU groups.
As the focus of the intervention was on changing so-
cial support for recovery from opiate dependence, the
IPDA data are explored in more detail. For the whole
sample, the median number of people considered
important with whom they had contact in the preceding
90 days was 5 (range 2–10). Family members were the
most frequently named group (median = 3.2, range 0–
10), followed by friends (1.4, 0–6), members of the
recovery community (0.5, 0–4), and co-workers (0.2, 0–
4). Nearly 80% (66/83) could name 4 ‘very important
people’, and none of this sub-group accepted or
Table 1 Differences in the primary outcome measure between the three trial arms
Median days abstinent from heroin
Baseline 3 months 12 months Relative risk (95% CI)
vs TAU 3 months
Relative risk (95% CI)
vs TAU 12 months
B-SBNT 15 18 17 0.96 (0.79–1.17) 0.96 (0.78–1.17)
PGS 18 18 18 0.93 (0.77–1.13) 1.00 (0.83–1.20)
TAU 20 23 25
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encouraged drug use. A clear majority of the reported
network (84%) supported the participant attending drug
treatment services. Heavy drug users made up just 7% of
the reported network, and a median of 4 out of 5 net-
work members named were totally abstinent from illicit
drugs.
Discussion
The National Institute for Health and Care Excellence
(NICE) has highlighted the limits of the evidence base
for psychosocial treatments for heroin dependence, but
also noted the promise of family and social network in-
terventions [45]. Here an attempt was made to specific-
ally adapt the SBNT intervention to make it more
suitable for use within drug treatment services by using
the elements found to be most important in the process
of change [26]. Although it was possible to train clinical
staff to an adequate level of competence (fidelity analysis
of the audiotapes showed that B-SBNT sessions were
clearly distinguishable from the PGS and TAU sessions),
and to follow-up a high proportion (84%) of study par-
ticipants for 12 months, the study highlights two major
challenges to implementation of this feasibility study in
UK treatment services.
The first relates to organisational barriers to conducting
research with this population in OST services in England.
The current national policy of re-tendering the contract
to provide treatment services [46, 47] means that the ser-
vice provider may change every three years. Not only is
this disruptive to patients and staff, but it also presents a
significant impediment to conducting clinical research.
One site in this trial was unaffected by re-commissioning
during the trial period and recruited 90% of its target in
the available time; the other underwent a re-
commissioning process three months after the study
started and recruited a third of its target. The need to
compete to win a new contract possibly drew vital re-
sources away from the clinical ‘front line’ and distracted
otherwise motivated clinicians from their research role. As
substance use disorders have come to be understood as
chronic illnesses that require a chronic disease manage-
ment model, so continuity of treatment provision be-
comes more important [48]. In a review of the evidence
base for Recovery Oriented Systems of Care, White high-
lights stability in terms of funding, organizational owner-
ship and workforce is a key measure of quality [49].
The second challenge concerns the potential partici-
pants’ reluctance to engage in psychosocial therapy. The
population under study was the most intractable group
in treatment i.e. opiate dependent individuals who had
received OST at flexible dosing levels for at least one
year but had not stopped using heroin. Many had been
receiving OST at a therapeutic dose for at least 5 years
and were still reporting heroin use on more than half of
the preceding 28 days, in addition to regular use of crack
cocaine. Across the three sites 552 patients met the eligi-
bility criteria, but only 83 (15%) started the study. Over-
all 155 (28%) patients refused the offer of participating
when they were initially assessed or failed to attend the
assessment appointment. This reflects the difficulty of
making contact with patients of UK OST services, but
also their reluctance to receive interventions in addition
to an OST prescription. Less than two-thirds of the sam-
ple (51/83) saw their goal of treatment to be abstinent
from both illicit (i.e. heroin) and prescribed (i.e. OST) opi-
ates in the next year, with the rest either unsure of their
goal (n = 9) or aiming for abstinence from illicit opiates
only (n = 23). Nearly 20% of the participants did not at-
tend any treatment sessions during the study period, al-
though there was some evidence once engaged the social
network intervention was more likely to be completed (8
(30.7%) B-SBNT cases completed the full 4-session pro-
gram compared to 2 (7.4%) PGS participants).
The benefits of OST in this population are well docu-
mented [50], but the effect of additional psychosocial
treatment is not clear [4]. There is a body of evidence
that shows that adding more service produces better
outcomes [51–53], but when specific psychosocial inter-
ventions are added the evidence base is not as strong
[54]. This study found no difference in any measure be-
tween the three treatment arms. This mirrors recent
findings in prescription opioid dependence where the
addition of counselling to OST made no difference to
drug related outcomes [55], and in treatment-refractory
opioid dependent individuals where there was no
evidence for the superiority of a cognitive behavioural
intervention over an active comparison condition [56].
Another study cited loss of hope as a reason for non-
attendance at counselling sessions [57]. This was a feasi-
bility study of a promising intervention, and the next
planned step was to move to a larger, adequately pow-
ered trial. However, for this study to lead to a definitive
trial it would have needed to provide an indication of
positive change in the main outcome measure for the
social network intervention. Incomplete recruitment
meant a lack of power to determine potentially small
effects, and it is also likely that the ‘dose’ of social net-
work treatment administered was inadequate to change
behaviour in a group with such complex and enduring
needs. During the 6-week study period participants
attended less than 50% of the treatment sessions offered
to them (active intervention or routine appointments),
and less than half of the B-SBNT cases involved a social
network member in a treatment session.
Orford has called for a shift in the way addiction re-
search is conducted, with less emphasis on studying
named interventions and more focus on studying change
processes within the broader, longer-acting systems of
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which treatment is part [58]. Previous research has shown
that some patients benefit from OST without the need for
additional non-medical treatment, whereas others only
benefit when an adequate dose of psychosocial interven-
tion is added [53, 59]. Rates of abstinence-based recovery
are low in this population, and McKay has argued that
treatments need to link patients to reinforcers that will
make continued abstinence more appealing [60]. Interven-
tions that extend beyond the individual to the family and
wider social network are a good way of doing this. How-
ever, in order to increase the amount of exposure to thera-
peutic components it may be necessary to incorporate
‘evidence based practices’ (EBPs) into routine care [61], ra-
ther than trying to deliver a whole new additional inter-
vention package. A greater emphasis on finding suitable
reinforcers for participation may be needed, and contin-
gency management strategies have shown promise in this
population [62, 63]. The variability in therapist involve-
ment in this trial also reminds us that there should also be
a greater focus on studying therapist factors in existing
treatment staff, and future attempts might start by inte-
grating social network-orientated thinking into a whole
team approach.
Conclusions
This study has shown that promising interventions to
harness social network support for change are feasible in
the OST population, and staff can be trained to deliver
them. However, further work is required to tailor the
intervention to this population, possibly through the
addition of more potent reinforcers to attend therapy
sessions. It has also highlighted the need for a stable
workforce and organizational structure within which to
deliver elements of a chronic care model.
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